No effect of intralesional injection of interferon on moderate cervical intraepithelial neoplasia.
Women with histologically confirmed cervical intraepithelial neoplasia grade 2 (CIN 2) were treated in a double blind investigation of treatment with intralesioneal interferon alpha-2b (Intron a). Before treatment commenced, the existence and the types of human papilloma-virus (HPV) were assessed in [35S] methionine-labelled cervical biopsies by the determination of specific protein markers. Pronounced side effects occurred in all the women treated with interferon and the trial was stopped when it became apparent that there were no obvious beneficial effects. No positive benefits of interferon treatment were detected on either the CIN 2 or on the persistence of HPV types. It is concluded that intralesioneal injection of interferon has no place in the treatment of CIN.
Frost
L
L
Department of Obstetrics and Gynecology, Aarhus Municipal Hospital, Denmark.
Skajaa
K
K
Hvidman
L E
LE
Fay
S J
SJ
Larsen
P M
PM
D000328:Adult; D002584:Cervix Uteri / Q000382:microbiology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D007370:Interferon Type I / Q000008:administration & dosage*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D027383:Papillomaviridae / Q000302:isolation & purification; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D014412:Tumor Virus Infections / Q000188:drug therapy; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*
D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins